StockIQpro
NASDAQ:OKUR

OnKure Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

OnKure Therapeutics, Inc. reported net income of −$59.5M in fiscal 2025. Free cash flow was −$51.9M, and the diluted share count rose 292.1%.Summary generated from OnKure Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 12, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−74.4%
Debt / equityn/a
Free cash flow−$51.9M
FCF marginn/a
Share count change+292.1%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/a0n/a
Operating income−40−54−37−54−63
Net income−40−52−35−53−60
Free cash flow−38−48−35−51−52

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations